Acting against epidemics in low- and middle-income countries

Show in media library: 
bioMérieux has a longstanding presence in low- and middle-income countries. The Company’s teams are involved in research programs and actions in the field to provide an adequate response to the risk of epidemics.

Joining forces to combat plague outbreaks in Madagascar

We are continuing our collaboration with the Institut Pasteur of Madagascar to combat the plague through a study launched in 2018 to improve the diagnosis of this endemic disease. The clinical study, which is funded by bioMérieux in collaboration with the Institut Mérieux, focuses on diagnosing the plague using the BIOFIRE® FILMARRAY® Global Fever Panel RUO (Research Use Only) developed by BioFire Defense. 

The Company also supported the 13th International Yersinia Symposium from September 16 to 19 in Madagascar, the first event organized in Africa on the Yersinia genus. The Yersinia pestis bacterium causes the plague, a zoonotic disease transmitted by fleas. The plague, which remains endemic in Asia, America and Africa, has caused three pandemics and millions of deaths.

Contributing to better infectious disease diagnostics in Haiti and Cambodia

bioMérieux continues to support infectious disease diagnostics in resource-limited countries by making donations of reagents.

  • In Haiti, the Company donated BIOFIRE® FILMARRAY® Gastro-Intestinal Panels to the Gheskio Centers to improve the diagnosis of gastro-intestinal infections
  • In Cambodia, BIOFIRE® FILMARRAY® Meningitis-Encephalitis and Respiratory Panels were donated to the Angkor Hospital for Children to improve diagnoses among children admitted to the Emergency Room with suspected neuro-meningitis or respiratory infections.

Doing our part to improve diagnostic testing of pediatric fevers

bioMérieux provides support for a research program on pediatric fevers in rural areas of six countries in Southeast Asia by donating BIOFIRE® FILMARRAY® systems and Respiratory Panels. This research program is being developed by the Mahidol Oxford Tropical Medicine Research Unit (MORU, Faculty of Tropical Medicine, Bangkok, Thailand). The contract was signed in December 2019 and patient enrollment is scheduled for 2020.